tldrdailynews.com logo

FDA Panel Unanimously Rejects Intarcia's Diabetes Treatment Implant

1 min read
Source: Endpoints News
FDA Panel Unanimously Rejects Intarcia's Diabetes Treatment Implant
Photo: Endpoints News
TL;DR Summary

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee unanimously rejected Intarcia's ITCA 650, an implant for treating type 2 diabetes, stating that the benefits of the drug-device combination do not outweigh the associated risks, including acute kidney injury and major adverse cardiovascular events.

Topics:business#drug-device-combination#fda#healthcare#intarcia#itca-650#type-2-diabetes
Share this article
  1. FDA advisors unanimously reject Intarcia's embattled type 2 diabetes treatment  Endpoints News
  2. FDA panel votes down Intarcia's twice-rejected, long-term diabetes drug implant  FierceBiotech
  3. FDA advisory panel rejects drug-device combination to treat Type 2 diabetes  The Boston Globe
  4. Intarcia's device-drug diabetes therapy shut down by FDA panel  STAT
  5. Intarcia’s Diabetes Drug-Device Implant Unanimously Rejected by Adcomm  BioSpace
  6. View Full Coverage on Google News

Reading Insights

Total Reads

0

Unique Readers

11

Time Saved

0 min

vs 1 min read

Condensed

69%

137 → 43 words

Want the full story? Read the original article

Read on Endpoints News